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Abstract 
Major bleeding is a common complication following percutaneous coronary 
intervention (PCI), although little is known about how bleeding rates have changed over 
time and what has driven this. We analyzed all patients undergoing PCI in England and 
Wales from 2006 to 2013.  Multivariate analyses using logistic regression models were 
performed to identify predictors of bleeding in order to identify potential factors 
influencing bleeding trends over time. 545,604 participants who had PCI in England 
and Wales between 2006 and 2013 were included in the analyses.  Overall bleeding 
rates declined from 7.0 (CI:6.2–7.8) per 1000 procedures in 2006 to 5.5 (CI:4.7–6.2) 
per 1000 in 2013. Increasing age, female sex, GPIIb/IIIa inhibitor use and circulatory 
support was independently associated with increased risk of bleeding complications 
whilst radial access and vascular closure device use were independently associated with 
decreases in risk.  Decreases in bleeding rates over time were associated with radial 
access site, and changes in pharmacology, but this was offset by greater proportion of 
ACS cases and more the adverse patient clinical demographics. In conclusion, Major 
bleeding complications after PCI has declined due to changes in access site practice 
and decreased usage of GPIIb/IIIa inhibitors, but this is offset by the increase of patients 
with higher propensity to bleed. Changes in access site practice nationally have the 
potential to significantly reduce major bleeding following PCI. 
Keywords: percutaneous coronary intervention, bleeding, trends 
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Introduction 
 Major bleeding is one of the most common complications following 
percutaneous coronary intervention (PCI), independently associated with a 3-fold 
increase in mortality 1and contributing to 12% of all in-hospital PCI mortalities 2. The 
average age and comorbid burden of patients undergoing PCI has increased over time 
with more potent pharmacotherapy and worsening patient clinical risk profiles that 
would tend to increase incident major bleeding3-5, whilst changes in access site practice 
towards radial would reduce major bleeding6-8. Temporal changes in major bleeding 
therefore represents a complex dynamic between changes in these competing risks. 
Access site related bleeding complications account for half of all bleeding 
complications observed post PCI9. In the United Kingdom (UK) there has been a 
national change in access site practice towards radial with 80% of all PCI procedures 
undertaken radially7,10. We report changes in temporal bleeding rates in a large 
contemporary unselected all-comer national cohort in the UK from British 
Cardiovascular Intervention Society (BCIS) database studying changes in clinical and 
procedural demographics, pharmacotherapy and access site practice, assess 
associations with peri-procedural bleeding complications, and determine which factors 
associate most with the temporal changes in bleeding complications observed. 
Methods 
This is a retrospective analysis of prospectively collected national data for all 
patients undergoing PCI in England and Wales from January 2006 to December 2013. 
BCIS records information on PCI practice in the UK with data collection managed by 
the National Institute of Cardiovascular Outcomes Research (NICOR)7,8,10. In-hospital 
major bleeding complications were defined as a composite of reported gastrointestinal 
bleed, intracerebral bleed, retroperitoneal hematoma, tamponade, blood or platelet 
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transfusion, or an arterial access site complication requiring surgical intervention6-8. 
Procedures were divided into 2 groups, based on the indication for PCI, either elective 
or acute coronary syndrome (ACS). Procedures performed for unstable angina (UA), 
non ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation 
myocardial infarction (STEMI) formed the ACS group. Analyses were carried out on 
the whole cohort, and then in elective and ACS cohorts separately. 
Procedures were excluded if in-hospital outcomes, coronary syndrome, or 
patient age or gender were missing from the dataset. Procedures in which the access 
site was unclear or missing, or where multiple access sites were recorded and the 
primary access site used for the procedure could not be identified were also excluded.   
For basic analyses of demographics, procedural details and unadjusted 
outcomes, continuous variables were evaluated as median and interquartile range (IRQ), 
whilst categorical variables were reported using frequencies and proportions (in 
percentages). Chi-square tests were used to assess the significance of differences in 
proportions between groups for categorical variables. Kruskal-Wallis rank sum test was 
used for continuous variables. All statistical tests were two-tailed and an alpha of 5% 
(for significance) was used throughout. In the present analysis, we modified the risk 
score published by Mehran et al11. to define the baseline risk of major bleeding. Our 
modified Mehran score, was calculated and an integer score assigned for each category 
as previously reported by our group12. 
Multiple imputation methods were used in order to reduce potential bias created 
by missing data. To this aim, we used the mice R package, version 2.2513. Chained 
equations were used to impute data for all variables with missing values to generate 10 
dataset instances for use in the analyses. 
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Unadjusted annual bleeding rates were estimated using the whole cohort and 
then the two groups, Elective and ACS. We used simple linear regressions to quantify 
the association between year of procedure and annual bleeding rates. Multivariate 
analyses using logistic regression model were performed to identify predictors of 
bleeding in order to identify potential factors influencing bleeding trends over time. We 
included all variables assumed clinically relevant as explanatory variables in the model: 
age, gender, smoking status, diabetes, peripheral vascular disease (PVD), hypertension, 
hypercholesterolemia, renal disease, previous coronary artery bypass graft (CABG), 
previous myocardial infarction (MI), previous stroke, previous PCI, left ventricular 
ejection fraction (LVEF), indication for PCI, access site, vascular closure device (VCD), 
stent, left main stem artery use, multivessel PCI, cardiogenic shock (CS), intra-aortic 
balloon pump (IABP) use, ventilatory support, circulatory support, glycoprotein 
IIb/IIIa inhibitors (GPI) use, antiplatelet drug, and bivalirudin use . We used the base 
stats R package to build the models. Odd ratios and confidence intervals were obtained 
after pooling the fitted model coefficients of the 10 complete dataset instances per 
group according to using the mice R package14. Areas under the receiver operator 
curves (AUCs) were estimated in order to assess model robustness for prediction.  
Our aim was to identify possible factors influencing the changes in bleeding 
rates over time and to quantify their effects Firstly, we took the annual average of the 
predicted bleeding log odds predicted by the aforementioned logistic models and 
decomposed them into their additive terms, one for each explanatory variable. We 
grouped the terms in (functional) factors taking into account their associations with the 
bleeding outcome, as follows: clinical demographics (age, gender, smoking status, 
diabetes, PVD, hypertension, hypercholesterolemia, renal disease, previous CABG, 
previous MI, previous stroke, previous PCI, and LVEF); indication for PCI; access site; 
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VCD use; CS and IABP; other procedural characteristics (stent, left main stem artery, 
and multivessel PCI); and pharmacology (GPI, antiplatelets, and bivalirudin). We 
reported scores measuring relative factor contributions to the changes in bleeding rates 
over time. This approach provides a graphical representation of the relative factor 
contributions and allows us to explore them year-by-year. Finally, and with the aim to 
quantify the influence of factors on the bleeding rate trends, we started with a new 
simple univariate logistic regression model (Supplementary methods).  
Results 
 A total of 577,471 procedures were undertaken in England and Wales between 
2006 and 2013 of which 545,604 (94.5%) were included in the analyses (Figure 1). 
Changes in clinical demographics, procedural characteristics and pharmacology over 
this period of time are summarized in Table 1a, for the whole cohort, and Tables 1b and 
1c for elective PCI and ACS groups, respectively. Supplementary Table S1 gives details 
of missing value levels presented in the data. We observed that PCI volume increased 
from 51,850 procedures in 2006 to 78,398 in 2013, mainly driven by the increase in 
procedures for ACS. During this period of time, the average age of patients increased; 
their clinical risk factor profile worsened and the proportion of PCI procedures on 
patients with cardiogenic shock or requiring ventilatory / circulatory support increased. 
The use of GPIIb/IIIa inhibitors declined during the study period, whilst bivalirudin 
and newer anti-platelet agent use increased. Finally radial access grew to become the 
default access site used for PCI in 68.5% of procedures in 2013. Bleeding risk as 
quantified by the Mehran risk score increased for both elective and ACS PCI 
indications over time (supplementary Figure 1).  
 Figure 2 shows the results of using simple linear regressions to estimate 
unadjusted bleeding rate trends over time. Overall bleeding rates declined from 7.0 (CI: 
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6.2 – 7.8) per 1000 procedures in 2006 to 5.5 (CI: 4.7 – 6.2) per 1000 in 2013. Decreases 
in the rates were observed in both groups, being more pronounced in ACS. The bleeding 
complication rate in the elective PCI group dropped from 4.9 (CI: 4.1 – 5.7) per 1000 
in 2006 to 3.9 (CI: 3.2 – 4.7) per 1000 in 2013, whilst in the ACS group, from 8.9 (CI: 
7.8 – 10.1) per 1000 to 6.2 (CI: 5.1 – 7.4) per 1000 during the same period. Results of 
the analyses using multivariate logistic regressions are summarized in Table 2. In both 
groups, elective and ACS indications for PCI, increasing age, female sex, GPIIb/IIIa 
inhibitor use and circulatory support was independently associated with increased risk 
of bleeding complications whilst radial access and VCD use were independently 
associated with decreases in risk. 
 In Figure 3, we report relative contributions to the overall bleeding change score, 
using 2006, the initial year, as the baseline. It can be observed in this figure that most 
of the decrease in bleeding rates over time was associated with the adoption of radial 
access site, and by changes in pharmacology, although this was offset by the changes 
such as changes in PCI indications towards ACS cases and more the adverse clinical 
demographics of the patients.Results of the quantification of influencing factors in 
bleeding trends as estimated using multiple multivariate regression models (model_0 to 
model_7) are presented in Table 3. In this table, large positive attenuation values 
indicate a strong association of a particular factor with lower bleeding rates. We 
observed that the reported results in Table 4 are in the same direction as the ones using 
the relative score contributions (Figure 3). In the three groups, access site choice was 
the most influential factor associated with lower bleeding rates over time. 
Pharmacology was another important factor associated with lower bleeding rates. 
Additionally, although to a lesser extent, VCD use (in all cohorts), procedural 
characteristics (in both the whole cohort and ACS group) contributed to lower the 
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bleeding rates over time. In contrast, the indication for PCI tended towards increasing 
the bleeding rates over time. 
Discussion 
 In the current analysis of over half a million PCI procedures, our data suggests 
that significant temporal changes in clinical and procedural demographics, access site 
practice and pharmacology has been accompanied by a decline in incident rates of in-
hospital major bleeding. Our analysis suggests that these reductions in major bleeding 
relate mainly to changes in access site practice and pharmacology driven by decreased 
usage of glycoprotein IIb/IIIa inhibitors, although offset by the increase in PCI cases 
undertaken for ACS and worsening clinical demographic profiles of patients.  
 Temporal changes in incident major bleeding complications represent a 
complex dynamic between changes in pharmacological therapy, indications for PCI, 
co-morbid burden, clinical demographics, procedural characteristics and access site 
practice1,9. This dynamic will vary across different healthcare systems. Analysis of data 
from a Canadian registry of 14,111 patients with non-ST elevation myocardial 
infarction (NSTEMI) between 1999 and 2008 reported no significant changes in major 
bleeding rates over time15 despite changes in pharmacotherapy and interventional 
strategies. In contrast, data derived from the US CathPCI Registry reported 20% 
temporal reductions in post-PCI bleeding observed in patients undergoing PCI for 
elective and NSTEMI indications, although adjusted bleeding rates in the STEMI 
cohort remained similar16. In national registry from Sweden in elderly patients 
undergoing PCI for STEMI indications, incident major bleeding rates remained similar 
over a decade5. A further analysis derived from the CathPCI registry over a 3-year 
period (2009-2012) showed that bleeding rates declined over the period studied, 
although when compared with hospitals with very low or low increase in the use of 
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radial access, the decline in risk-adjusted overall bleeding over time was greater at 
hospitals with moderate or high increase in the use of radial access (RR, 0.51; 95% CI, 
0.43–0.61 versus RR, 0.69; 95% CI, 0.63–0.74; P for comparison, 0.002)17. Our 
analysis suggests that the decline in major bleeding complications observed in the UK, 
are mainly associated with the national change in access site practice towards radial, 
changes in pharmacological practices, particularly declining use of GP IIb/IIIa 
inhibitors and to a lesser extent VCD use. However, this effect is attenuated by the 
worsening bleeding risk profile of patients undergoing PCI (as evidenced by the 
temporal increase in Mehran bleeding risk score) and the increase in PCI procedures 
undertaken for ACS indications. Our analysis is the first to study this in a healthcare 
system where there has been a national change in access site practice towards radial 
and the first to study the contribution of all aspects of the PCI procedure and patient 
clinical characteristics that may contribute to changes in incident bleeding recorded. 
Interestingly, data from the CathPCI registry studying changes in national bleeding 
rates between 2005-2009 suggested that changes in access site practice in the US 
contributed minimally to the reduction in bleeding rates recorded, although only 1.5% 
of cases were undertaken radially during this time16. This is in contrast to radial rates 
of close to 70% reported in the current analysis. 
 Changes in anti-thrombotic strategies such as decreased utilization of GPIIb/IIIa 
inhibitors and concomitant increases in bivalirudin contributed to close to 50% of the 
reduction in major bleeding observed in the NCDR analysis16. Our analysis suggests 
that after changes in access site practice, changes in pharmacological practice were 
most closely associated with reduced major bleeding complications with similar 
attenuations of bleeding risk reported to those observed in the NCDR (52.8% in all PCI 
indications). Specifically, we observed a reduction in GPIIb/IIIa inhibitor usage from 
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35% to 16.7% in the whole population and 50.6% to 23.2% in the ACS population 
reflecting changes in contemporary anticoagulant practice in PCI. Increases in the use 
of newer antiplatelet agents such as Ticagrelor and Prasugrel over time were observed, 
although neither contributed to temporal changes in major bleeding that we observed. 
Our analysis shows that the average age of patients has increased, with more females 
undergoing PCI, and a greater prevalence of cardiovascular risk factors, with 
corresponding increases in the calculated bleeding risk of the patients. Similarly, our 
data show that the proportion of PCI cases undertaken for ACS indications has 
increased, thereby further contributing to worsening bleeding outcomes18-20.  
 Our analysis suggests that the growth of transradial access (TRA) from 17% in 
2006 to close to 70% in 2013 has been most strongly associated with the reduction in 
national major bleeding rates observed in both the elective and ACS settings. Both 
national registry12 and randomized controlled trial data21-23 has shown that TRA is 
independently associated with reduced mortality and major bleeding risk in high-risk 
patient groups. Temporal changes in the incidence of major bleeding complications 
represents a complex dynamic between changes in pharmacological practices, PCI 
indication, co-morbid burden, clinical demographics, procedural characteristics and 
access site practice, and this will change annually dependent on the annualized 
prevalence of each factor. Furthermore, the contribution of each of these competing 
“risks” to the final incident bleeding rates will vary in different countries dependent on 
differences in case mix, clinical and pharmacological practice, with the greatest benefit 
to be gained in countries that are at the earliest stages of radial adoption.  
 Our analysis has several limitations. Firstly, bleeding complications are self-
reported and are not adjudicated / validated by BCIS potentially resulting in under-
reporting. Secondly, the definition of major bleeding that is used in the BCIS dataset is 
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different from those frequently used in clinical trials (1) making comparisons with other 
studies / trials difficult, although has remained constant during the period studied. The 
thresholds for blood transfusions (a component of the BCIS definition for major 
bleeding) may have changed over time that may introduce confounding and the BCIS 
dataset does not differentiate between blood transfusions given for bleeding 
complications and those for chronic anemia. Thirdly, whilst the BCIS dataset captures 
CV risk factors, it does not capture other measures of co-morbid burden24 that may have 
contributed to the changes in incident bleeding reported here. Finally, our observational 
data can only report associations and causal relationships cannot be inferred.  
 In conclusion, observe significant changes in clinical and procedural 
demographics, access site practice and pharmacology over time in patients undergoing 
PCI in England and Wales, accompanied by a decline in the crude incident rates of in-
hospital major bleeding complications. Our analysis suggests that these national 
decreases in major bleeding are most strongly associated with changes in access site 
practice and decreased usage of glycoprotein IIb/IIIa inhibitors, although this has been 
offset by the increase in proportion of PCI cases undertaken for ACS indications and 
the treatment of patients who are at higher risk of bleeding complications. Our data 
suggest a change in access site practice nationally has the potential to significantly 
reduce major bleeding following PCI. 
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Table 1c: Baseline patient demographics, procedural details, and pharmacology (ACS 
only). 
Table 2: Summary results after fitting multivariate logistic regression models on the 
whole cohort and the two subsets.  
Table 3: Influence of changes in factors on temporal trends in bleeding rates. 
Supplementary Table S1: Proportion of missing values presents in the original dataset. 
Supplementary Figure 1: Mehran bleeding risk score for patients undergoing PCI for 
both elective and ACS. 
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Table 1a: Baseline patient demographics, procedural details, and pharmacology (whole cohort) 
Variable  2006 (51,850) 
2009 
(69,094) 
2011 
(75,016) 
2013 
(78,398) P-value Age (years) 64.5 (56.6 - 72.4) 65.1 (56.6 - 73.6) 65.3 (56.4 - 74.1) 65.0 (56.0 - 74.0) < 0.0001 Gender (Men) 38,133 (73.5%) 51,120 (74.0%) 55,544 (74.0%) 58,173 (74.2%) 0.30 Smoking status     < 0.0001   Never 12,135 (34.6%) 20,615 (33.3%) 24,346 (36.1%) 26,258 (36.8%)    Ex-smoker 14,968 (42.7%) 25,829 (41.8%) 26,107 (38.7%) 27,822 (39.0%)    Current 7,989 (22.8%) 15,386 (24.9%) 17,038 (25.2%) 17,332 (24.3%)  Diabetes Mellitus  7,115 (17.2%) 12,415 (18.5%) 13,937 (19.3%) 15,749 (21.2%) < 0.0001 Peripheral vascular disease 1,725 (3.7%) 3,171 (4.7%) 3,676 (5.0%) 3,728 (4.9%) < 0.0001 Hypertension 19,818 (42.2%) 37,000 (54.6%) 39,386 (53.7%) 41,730 (54.7%) < 0.0001 Hypercholesterolemia 21,514 (45.8%) 40,466 (59.7%) 39,913 (54.4%) 41,137 (53.9%) < 0.0001 Renal disease 913 (2.3%) 1,762 (2.6%) 1,814 (2.5%) 2,152 (2.9%) < 0.0001 Previous CABG 3,440 (14.3%) 4,777 (9.7%) 5,264 (9.1%) 5,682 (9.3%) < 0.0001 Previous myocardial infarction 11,820 (30.1%) 17,464 (28.5%) 18,747 (27.1%) 19,811 (26.8%) < 0.0001 Previous stroke 1,183 (2.5%) 2,786 (4.1%) 3,090 (4.2%) 3,164 (4.2%) < 0.0001 Previous Percutaneous coronary intervention 7,759 (18.2%) 14,824 (22.2%) 16,847 (23.0%) 19,052 (24.8%) < 0.0001 Left ventricular ejection fraction      < 0.0001    >50% 14,835 (74.7%) 25,320 (69.3%) 25,260 (70.8%) 28,081 (70.0%)    30%-50% 4,036 (20.3%) 8,659 (23.7%) 8,516 (23.9%) 9,468 (23.6%)    <30% 981 (4.9%) 2,537 (6.9%) 1,924 (5.4%) 2,568 (6.4%)  Indication for Percutaneous coronary intervention     < 0.0001    Elective 26,853 (53.6%) 29,088 (42.2%) 27,530 (36.8%) 27,426 (35.1%)   Unstable angina/Non ST-elevation acute    myocardial infarction 18,112 (36.1%) 26,226 (38.1%) 27,707 (37.0%) 29,608 (37.8%)   ST-elevation acute myocardial infarction 5,043 (10.1%) 13,428 (19.5%) 19,490 (26.0%) 21,081 (26.9%)    Stent thrombosis 104 (0.2%) 121 (0.2%) 123 (0.2%) 120 (0.2%)  Access site (Radial) 9,123 (17.6%) 27,199 (39.4%) 41,143 (54.8%) 53,703 (68.5%) < 0.0001 
Variable  2006 (51,850) 
2009 
(69,094) 
2011 
(75,016) 
2013 
(78,398) P-value Vascular closure device use 17,410 (33.6%) 23,719 (34.3%) 19,668 (26.2%) 15,141 (19.3%) < 0.0001 Stent     < 0.0001    None 2,768 (6.0%) 6,708 (10.2%) 7,214 (10.0%) 7,856 (10.4%)    Drug eluting 29,599 (63.7%) 41,010 (62.6%) 51,108 (70.9%) 60,569 (80.2%)    Bare metal 14,097 (30.3%) 17,815 (27.2%) 13,767 (19.1%) 7,099 (9.4%)  Left main stem artery 1,270 (2.7%) 2,139 (3.1%) 2,501 (3.4%) 3,651 (4.7%) < 0.0001 Multivessel Percutaneous coronary intervention 12,107 (23.8%) 12,821 (19.0%) 13,603 (18.3%) 14,209 (18.2%) < 0.0001 Cardiogenic shock 463 (1.0%) 1,145 (1.7%) 1,635 (2.2%) 2,205 (2.8%) < 0.0001 Intra-aortic balloon pump use 587 (1.1%) 1,073 (1.6%) 1,217 (1.6%) 1,064 (1.4%) < 0.0001 Ventilatory support 221 (0.6%) 648 (1.1%) 1,112 (1.7%) 1,411 (2.0%) < 0.0001 Circulatory support 628 (1.6%) 1,239 (1.9%) 1,491 (2.1%) 1,521 (2.0%) < 0.0001 Glycoprotein inhibitor use 15,706 (35.7%) 17,376 (27.3%) 14,880 (21.6%) 11,720 (16.4%) < 0.0001 Antiplatelet drug      < 0.0001    Clopidogrel 51,850 (100.0%) 69,027 (99.9%) 58,873 (92.0%) 53,228 (78.8%)    Prasugrel 0 (0.0%) 67 (0.1%) 5,122 (8.0%) 4,718 (7.0%)    Ticagrelor 0 (0.0%) 0 (0.0%) 26 (0.0%) 9,597 (14.2%)  Bivalirudin 440 (0.8%) 452 (0.7%) 3,349 (4.5%) 4,957 (6.3%) < 0.0001 Bleeding 328 (0.6%) 417 (0.6%) 469 (0.6%) 435 (0.5%) < 0.0001 
Table 1b: Baseline patient demographics, procedural details, and pharmacology (Elective procedures only) 
Variable  2006 (26,853) 
2009 
(29,088) 
2011 
(27,530) 
2013 
(27,426) P-value Age (years) 64.9 (57.7 - 72.2) 65.7 (58.3 - 73.3) 66.0 (58.3 - 73.7) 66.0 (58.0 - 74.0) < 0.0001 Gender (Men) 19,870 (74.0%) 21,651 (74.4%) 20,774 (75.5%) 20,813 (75.9%) < 0.0001 Smoking status     < 0.0001   Never 6,916 (38.5%) 9,699 (37.3%) 9,840 (39.8%) 9,987 (40.2%)    Ex-smoker 8,561 (47.6%) 12,775 (49.1%) 11,713 (47.4%) 11,752 (47.4%)    Current 2,494 (13.9%) 3,550 (13.6%) 3,184 (12.9%) 3,079 (12.4%)  Diabetes Mellitus 3,819 (17.9%) 6,012 (21.2%) 5,778 (21.8%) 6,217 (23.9%) < 0.0001 Peripheral vascular disease  924 (3.8%) 1,446 (5.1%) 1,487 (5.5%) 1,306 (4.9%) < 0.0001 Hypertension 10,748 (44.4%) 17,235 (60.3%) 16,451 (60.8%) 16,620 (62.0%) < 0.0001 Hypercholesterolemia 11,844 (49.0%) 19,119 (66.9%) 16,983 (62.8%) 17,048 (63.6%) < 0.0001 Renal disease 392 (2.0%) 684 (2.4%) 597 (2.2%) 704 (2.6%) < 0.0001 Previous coronary artery bypass graft 1,864 (15.8%) 2,563 (12.3%) 2,563 (11.9%) 2,647 (12.2%) < 0.0001 Previous myocardial infarction 6,139 (30.5%) 9,024 (34.7%) 8,696 (34.5%) 9,072 (34.8%) < 0.0001 Previous stroke 554 (2.3%) 1,099 (3.9%) 1,015 (3.8%) 1,024 (3.8%) < 0.0001 Previous Percutaneous coronary intervention  5,101 (23.3%) 9,141 (32.5%) 9,609 (35.8%) 10,649 (39.5%) < 0.0001 Left ventricular ejection fraction     < 0.0001   >50% 8,820 (82.3%) 13,755 (79.3%) 12,925 (80.7%) 13,709 (80.6%)   30%-50% 1,571 (14.7%) 2,769 (16.0%) 2,592 (16.2%) 2,711 (15.9%)    <30% 322 (3.0%) 829 (4.8%) 497 (3.1%) 586 (3.4%)  Access site (Radial) 4,325 (16.1%) 10,822 (37.2%) 14,187 (51.5%) 17,902 (65.3%) < 0.0001 Vascular closure device use 8,990 (33.5%) 10,521 (36.2%) 7,926 (28.8%) 6,100 (22.2%) < 0.0001 Stent     < 0.0001   None 1,624 (6.8%) 3,792 (13.8%) 3,474 (13.2%) 3,562 (13.6%)    Drug eluting 16,295 (68.1%) 18,522 (67.4%) 19,708 (75.0%) 21,117 (80.9%)    Bare metal 5,996 (25.1%) 5,186 (18.9%) 3,080 (11.7%) 1,430 (5.5%)  Left main stem artery 651 (2.7%) 1,031 (3.6%) 1,024 (3.8%) 1,454 (5.4%) < 0.0001 Multivessel Percutaneous coronary intervention 6,750 (25.7%) 6,156 (21.8%) 5,991 (21.9%) 5,898 (21.6%) < 0.0001 Cardiogenic shock 3 (0.0%) 5 (0.0%) 4 (0.0%) 15 (0.1%) 0.022 
Variable  2006 (26,853) 
2009 
(29,088) 
2011 
(27,530) 
2013 
(27,426) P-value Intra-aortic balloon pump use 71 (0.3%) 70 (0.2%) 52 (0.2%) 40 (0.1%) < 0.0001 Ventilatory support 33 (0.2%) 54 (0.2%) 93 (0.4%) 75 (0.3%) < 0.0001 Circulatory support 79 (0.4%) 85 (0.3%) 89 (0.3%) 70 (0.3%) 0.0008 Glycoprotein inhibitor use 4,745 (21.2%) 2,347 (8.9%) 1,397 (5.5%) 989 (3.9%) < 0.0001 Antiplatelet use      < 0.0001   Clopidogrel 26,853 (100.0%) 29,076 (100.0%) 27,120 (98.5%) 25,950 (94.6%)    Prasugrel 0 (0.0%) 12 (0.0%) 407 (1.5%) 618 (2.3%)    Ticagrelor 0 (0.0%) 0 (0.0%) 3 (0.0%) 858 (3.1%)  Bivalirudin 150 (0.6%) 34 (0.1%) 62 (0.2%) 92 (0.3%) < 0.0001 Bleeding 132 (0.5%) 118 (0.4%) 119 (0.4%) 126 (0.5%) 0.052 
 
Table 1c: Baseline patient demographics, procedural details, and pharmacology (ACS only) 
Variable 2006 (24,997) 
2009 
(40,006) 
2011 
(47,486) 
2013 
(50,972) P-value Age (years) 64.0 (55.1 - 72.6) 64.5 (55.3 - 73.9) 65.0 (55.3 - 74.6) 65.0 (55.0 - 74.0) < 0.0001 Gender (Men) 18,263 (73.1%) 29,469 (73.7%) 34,770 (73.2%) 37,360 (73.3%) 0.49 Smoking status     < 0.0001   Never 5,219 (30.5%) 10,916 (30.5%) 14,506 (33.9%) 16,271 (34.9%)    Ex-smoker 6,407 (37.4%) 13,054 (36.5%) 14,394 (33.7%) 16,070 (34.5%)    Current 5,495 (32.1%) 11,836 (33.1%) 13,854 (32.4%) 14,253 (30.6%)  Diabetes Mellitus  3,296 (16.5%) 6,403 (16.5%) 8,159 (17.9%) 9,532 (19.7%) < 0.0001 Peripheral vascular disease 801 (3.5%) 1,725 (4.4%) 2,189 (4.7%) 2,422 (4.9%) < 0.0001 Hypertension 9,070 (39.7%) 19,765 (50.4%) 22,935 (49.5%) 25,110 (50.7%) < 0.0001 Hypercholesterolemia 9,670 (42.3%) 21,347 (54.5%) 22,930 (49.5%) 24,089 (48.7%) < 0.0001 Renal disease 521 (2.7%) 1,078 (2.8%) 1,217 (2.7%) 1,448 (3.0%) 0.0006 Previous Coronary artery bypass graft 1,576 (12.9%) 2,214 (7.8%) 2,701 (7.5%) 3,035 (7.7%) < 0.0001 Previous myocardial infarction 5,681 (29.7%) 8,440 (24.0%) 10,051 (22.9%) 10,739 (22.4%) < 0.0001 Previous stroke 629 (2.8%) 1,687 (4.3%) 2,075 (4.5%) 2,140 (4.3%) < 0.0001 Previous Percutaneous coronary intervention 2,658 (12.8%) 5,683 (14.7%) 7,238 (15.6%) 8,403 (16.8%) < 0.0001 Left ventricular ejection fraction        >50% 6,015 (65.8%) 11,565 (60.4%) 12,335 (62.7%) 14,372 (62.2%)   30%-50% 2,465 (27.0%) 5,890 (30.7%) 5,924 (30.1%) 6,757 (29.2%)    <30% 659 (7.2%) 1,708 (8.9%) 1,427 (7.2%) 1,982 (8.6%)  Indication for Percutaneous coronary intervention     < 0.0001   Elective 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)    Unstable angina/Non ST-elevation acute myocardial infarction 18,112 (77.9%) 26,226 (65.9%) 27,707 (58.5%) 29,608 (58.3%)    ST-elevation acute myocardial infarction 5,043 (21.7%) 13,428 (33.7%) 19,490 (41.2%) 21,081 (41.5%)    Stent thrombosis 104 (0.4%) 121 (0.3%) 123 (0.3%) 120 (0.2%)  Access site (Radial) 4,798 (19.2%) 16,377 (40.9%) 26,956 (56.8%) 35,801 (70.2%) < 0.0001 Vascular closure device use 8,420 (33.7%) 13,198 (33.0%) 11,742 (24.7%) 9,041 (17.7%) < 0.0001 Stents     < 0.0001   None 1,144 (5.1%) 2,916 (7.7%) 3,740 (8.2%) 4,294 (8.7%)    Drug eluting 13,304 (59.0%) 22,488 (59.1%) 31,400 (68.5%) 39,452 (79.8%)    Bare metal 8,101 (35.9%) 12,629 (33.2%) 10,687 (23.3%) 5,669 (11.5%)  
Variable 2006 (24,997) 
2009 
(40,006) 
2011 
(47,486) 
2013 
(50,972) P-value Left main stem artery 619 (2.6%) 1,108 (2.8%) 1,477 (3.1%) 2,197 (4.4%) < 0.0001 Multivessel Percutaneous coronary intervention 5,357 (21.8%) 6,665 (17.0%) 7,612 (16.1%) 8,311 (16.4%) < 0.0001 Cardiogenic shock 460 (2.2%) 1,140 (2.9%) 1,631 (3.5%) 2,190 (4.3%) < 0.0001 Intra-aortic balloon pump use 516 (2.1%) 1,003 (2.5%) 1,165 (2.5%) 1,024 (2.0%) < 0.0001 Ventilatory support 188 (1.0%) 594 (1.7%) 1,019 (2.4%) 1,336 (2.9%) < 0.0001 Circulatory support 549 (2.8%) 1,154 (3.1%) 1,402 (3.1%) 1,451 (3.0%) 0.007 Glycoprotein inhibitor use 10,961 (50.6%) 15,029 (40.4%) 13,483 (31.0%) 10,731 (23.1%) < 0.0001 Antiplatelet use     < 0.0001   Clopidogrel 24,997 (100.0%) 39,951 (99.9%) 31,753 (87.0%) 27,278 (68.0%)    Prasugrel 0 (0.0%) 55 (0.1%) 4,715 (12.9%) 4,100 (10.2%)    Ticagrelor 0 (0.0%) 0 (0.0%) 23 (0.1%) 8,739 (21.8%)  Bivalirudin 290 (1.2%) 418 (1.0%) 3,287 (6.9%) 4,865 (9.5%) < 0.0001 Bleeding 196 (0.8%) 299 (0.8%) 350 (0.7%) 309 (0.6%) < 0.0001 
 
 
 
Table 2: Summary results after fitting multivariate logistic regression models on the whole 
cohort and the two subsets.  
 
(a) Explanatory variables, their coefficients expressed in odd ratios (OR), and their confidence 
intervals (in brackets). 
 All Elective PCI ACS (Intercept) 0.001 (0.000-0.001) 0.001 (0.000-0.001) 0.001 (0.001-0.001) Year 1.023 (1.005-1.041) 1.049 (1.018-1.082) 1.011 (0.989-1.033) Age 1.028 (1.024-1.031) 1.027 (1.020-1.034) 1.028 (1.024-1.032) Gender (Men)      Female 2.041 (1.898-2.194) 2.223 (1.946-2.540) 1.961 (1.799-2.138) Smoking status ( Never)      Ex-smoker 1.091 (1.003-1.187) 1.133 (0.983-1.307) 1.067 (0.963-1.183)   Current 1.046 (0.941-1.162) 1.022 (0.797-1.310) 1.044 (0.928-1.174) Diabetes 0.923 (0.843-1.012) 0.989 (0.844-1.159) 0.896 (0.802-1.001) Peripheral vascular disease 1.316 (1.147-1.509) 1.362 (1.054-1.760) 1.302 (1.106-1.531) Hypertension 1.141 (1.055-1.234) 1.206 (1.043-1.395) 1.116 (1.016-1.225) Hypercholesterolemia 1.184 (1.096-1.279) 1.120 (0.969-1.294) 1.207 (1.101-1.322) Renal disease 1.425 (1.214-1.673) 0.904 (0.603-1.354) 1.596 (1.338-1.903) Previous coronary artery bypass graft 0.804 (0.681-0.950) 0.797 (0.598-1.063) 0.820 (0.690-0.975) Previous myocardial infarction 0.901 (0.818-0.992) 0.969 (0.827-1.136) 0.865 (0.770-0.971) Previous stroke 1.280 (1.107-1.481) 1.353 (1.015-1.804) 1.255 (1.060-1.486) Previous Percutaneous coronary intervention 1.015 (0.918-1.122) 0.976 (0.838-1.137) 1.033 (0.905-1.178) Left ventricular ejection fraction (Good)      30%-50% 1.009 (0.916-1.112) 0.892 (0.700-1.137) 1.050 (0.935-1.179)   <30% 1.054 (0.907-1.226) 0.855 (0.575-1.270) 1.113 (0.950-1.303) Indication for Percutaneous coronary intervention (Elective)     Unstable angina/Non ST elevation acute myocardial infarction 1.191 (1.089-1.302)    ST elevation acute myocardial infarction 1.427 (1.272-1.600)  1.210 (1.096-1.336)*  Stent thrombosis 2.380 (1.564-3.622)  2.027 (1.331-3.087)* Access site (Femoral)      Radial 0.363 (0.330-0.399) 0.258 (0.213-0.312) 0.409 (0.366-0.457) Vascular disclosure device use 0.878 (0.810-0.951) 0.866 (0.752-0.996) 0.880 (0.798-0.970) Stent (None)      Drug eluting 0.820 (0.728-0.925) 0.951 (0.771-1.174) 0.748 (0.648-0.865)   Bare metal 0.857 (0.753-0.975) 0.866 (0.671-1.119) 0.816 (0.701-0.950) Left main stem artery 1.210 (1.039-1.410) 1.035 (0.757-1.416) 1.281 (1.075-1.526) Multivessel Percutaneous coronary intervention 1.093 (1.000-1.195) 1.209 (1.041-1.405) 1.035 (0.926-1.156) Cardiogenic shock 1.208 (1.019-1.432)  1.275 (1.071-1.518) Intra-aortic balloon pump use 1.129 (0.859-1.486) 0.453 (0.220-0.931) 1.331 (0.984-1.802) Ventilatory support 1.092 (0.892-1.336) 0.892 (0.327-2.435) 1.133 (0.922-1.392) Circulatory support 3.308 (2.522-4.339) 15.438 (8.721-27.328) 2.581 (1.906-3.494) Glycoprotein inhibitor use 1.953 (1.795-2.126) 2.134 (1.787-2.550) 1.877 (1.709-2.063) Antiplatelet drug (Clopidogrel)      Prasugrel 0.787 (0.645-0.961) 1.818 (0.961-3.438) 0.736 (0.597-0.908)   Ticagrelor 0.599 (0.435-0.826) 0.894 (0.284-2.815) 0.585 (0.418-0.818) Bivalirudin 1.684 (1.417-2.001) 1.440 (0.588-3.523) 1.704 (1.428-2.033) 
 
(b) Estimated average area under the receiver operator curves (AUC) 
(a) Explanatory variables, their coefficients expressed in odd ratios (OR), and their confidence 
intervals (in brackets). 
 All Elective PCI ACS 
 All Elective PCI ACS AUC 0.755 0.730 0.763 *UA/NSTEMI was used as baseline for the estimation of these ORs since there is no “Elective” category in the variable “Indication for PCI” within the ACS group.  
Table 3: Influence of changes in factors on temporal trends in bleeding rates. 
   
Comparison with Model 0 Comparison with Model 1 
Group Model† OR (95% CI)* Attenuation (%) P-value‡ Attenuation (%) P-value‡ All 0 0.964 (0.950-0.979)      1 0.952 (0.937-0.966) -34.08% <0.001    2 0.931 (0.916-0.945) -92.58% <0.001 -43.63% <0.001  3 1.015 (0.999-1.031) 141.52% <0.001 130.97% <0.001  4 0.958 (0.944-0.973) -15.47% <0.001 13.88% <0.001  5 0.955 (0.940-0.970) -25.42% <0.001 6.46% <0.001  6 0.945 (0.931-0.960) -51.88% <0.001 -13.27% <0.001  7 0.981 (0.965-0.998) 48.26% <0.001 61.41% <0.001 Elective 0 0.969 (0.942-0.996)      1 0.959 (0.932-0.986) -32.94% <0.001    -       3 1.028 (0.998-1.059) 189.74% <0.001 167.50% <0.001  4 0.966 (0.939-0.994) -8.05% <0.001 18.72% <0.001  5 0.954 (0.927-0.982) -46.61% <0.001 -10.29% <0.001  6 0.959 (0.932-0.987) -31.61% <0.001 1.00% <0.001  7 0.981 (0.953-1.010) 39.75% <0.001 54.68% <0.001 ACS 0 0.945 (0.928-0.963)      1 0.934 (0.917-0.951) -20.91% <0.001    2 0.919 (0.902-0.936) -48.38% <0.001 -22.72% <0.001  3 0.994 (0.975-1.013) 88.93% <0.001 90.85% <0.001  4 0.940 (0.923-0.958) -9.83% <0.001 9.16% <0.001  5 0.938 (0.920-0.956) -13.16% <0.001 6.41% <0.001  6 0.929 (0.912-0.947) -29.63% <0.001 -7.21% <0.001  7 0.972 (0.953-0.992) 49.43% <0.001 58.18% <0.001 †Logistic regression models for Bleeding:  model 0: univariate model with explanatory variable Year;  models 1 to 7: multivariate models with variable Year and adjusted for:  1) demographics; 2) demographics + indication for PCI; 3) demographics + access site; 4) demographics + VCD; 5) demographics + procedural characteristics (stent, left main stem artery, multivessel PCI); 6) demographics + CS/IABP; and 7) demographics + pharmacology. *Odd ratios between time variable (in years) and bleeding outcome (95% confidence interval in brackets).  ‡P-values of comparing models 0 and 1 with the others using likelihood test. 
 



Supplementary Methods 
To quantify the influence of factors on the bleeding rate trends, we started with a new 
simple univariate logistic regression model (Supplementary methods). using time as an ordered 
categorical explanatory variable (henceforth, model_0). Then, a more complex multivariate 
model containing model 0 and the clinical demographics covariates was created (model_1). 
Subsequent models containing model_1 were created, one for each factor influencing the 
trends, as follows: model_2 = model_1 + indication for PCI; model_3 = model_1 + access site; 
model_4 = model_1 + VCD use; model_5 = model_1 + procedural characteristics; model_6 = 
model_1 + CS/IABP; model_7 = model_1 + pharmacology. All models were fitted on multiply 
imputed data and pooled results were assessed against model_1 using likelihood ratio tests (A3) 
23, which take the between-imputation variability into account. As null hypothesis, we assumed 
no statistical difference between model_1 and models model_2 to model_7.  Influences of 
factors over temporal trends in bleeding were quantified by comparing the estimates for 1-year 
increases in time for model_1 against the corresponding estimates for time in the more complex 
models. If the added factor explained some of the temporal trends, we would expect the odds 
ratio for a 1-year increase in the time variable to attenuate towards 1. We reported the level of 
attenuation in odd ratios for the time variable after adding the covariates corresponding to a 
particular factor to the model_1.  
 
